Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pelthos Therapeutics (PTHS) Convertible Debt (2025)

Pelthos Therapeutics has reported Convertible Debt over the past 1 years, most recently at $31.4 million for Q4 2025.

  • Quarterly results put Convertible Debt at $31.4 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $31.4 million (changed N/A YoY), and the annual figure for FY2025 was $31.4 million, changed.
  • Convertible Debt for Q4 2025 was $31.4 million at Pelthos Therapeutics.
  • Over the last five years, Convertible Debt for PTHS hit a ceiling of $31.4 million in Q4 2025 and a floor of $31.4 million in Q4 2025.